Table 1.
Baseline demographic characteristics and treatment
| Variables (n = 30) | Median (IQR)/n (%) |
|---|---|
| Age (years) | 67 (63–77) |
| Male gender (n) | 27 (90) |
| Caucasian race (n) | 30 (100) |
| BMI (kg/m2) | 29 (26–35) |
| Obesity (BMI > 30 kg/m2) (n) | 12 (40) |
| Ischaemic heart disease (n) | 18 (60) |
| LVEF (%) | 25 (20–31) |
| LVEDD (mm) | 63 (58–69) |
| NYHA Class II/III/IV (n) | 0/26/4 (0/87/13) |
| Duration of CHF (years) | 5 (3–10) |
| Heart failure hospitalization (n) | 25 (83) |
| ≥3 heart failure hospitalizations (n) | 14 (47) |
| NT‐proBNP (pg/mL) | 3165 (880–8085) |
| NT‐proBNP > 1600 pg/mL (n) | 18 (64) a |
| Systolic blood pressure | 128 (113–136) |
| Diastolic blood pressure | 72 (66–81) |
| Mitral valve insufficiency ≥ moderate (n) | 4 (13) |
| Tricuspid valve insufficiency ≥ moderate (n) | 9 (30) |
| Atrial fibrillation/flutter (n) | 17 (57) |
| Diabetes mellitus (n) | 16 (53) |
| Arterial hypertension (n) | 20 (67) |
| COPD (n) | 4 (13) |
| History of malignant disease (n) | 5 (17) |
| Creatinine (μmol/L) | 120 (95–165) |
| eGFR (mL/min/kg) | 55 (34–70) |
| Cardiac devices | |
| ICD (n) | 22 (73) |
| CRT (n) | 10 (33) |
| Diuretics (n) | 28 (93) |
| Ivabradine (n) | 4 (13) |
| Digitoxin (n) | 1 (3) |
BMI, body mass index; CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter defibrillator; IQR, inter‐quartile range; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal prohormone of brain natriuretic peptide; NYHA, New York Heart Association.
a
Two values missing.